Cycuria Therapeutics

Executive Summary

Cycuria Therapeutics is a privately held Austrian biotechnology company founded in 2021, dedicated to developing next-generation protein-based targeted therapies for hematological malignancies and solid tumors. The company's lead focus is on acute myeloid leukemia (AML), a disease with high relapse rates and limited durable remission options. Cycuria's platform utilizes novel protein engineering to directly target leukemic cells and leukemic stem cells while sparing healthy tissue, potentially improving efficacy and reducing toxicity compared to conventional therapies. The approach aims to address a significant unmet need in AML, where patients often face poor outcomes despite current standards of care. As a preclinical-stage company, Cycuria is advancing its lead program toward entering the clinic, leveraging its proprietary platform to create a pipeline of candidates for additional cancer indications. The team is based in Vienna and benefits from the region's strong life sciences ecosystem. While early-stage, Cycuria's differentiated strategy and focus on a high-need area position it for potential value creation if clinical proof-of-concept is achieved.

Upcoming Catalysts (preview)

• Q4 2026IND-enabling studies completion for lead AML program60% success
• Q3 2026Series A funding round closing70% success
• Q2 2026Preclinical efficacy data presentation at scientific conference80% success